Fig. 2From: A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly in patients with anemia on hemodialysisMean Change from Baseline and 95% CI for Hemoglobin (g/dL) Over Time (ITT Population). BL, baseline; CI, confidence interval; Hgb, hemoglobin; ITT, intention-to-treatBack to article page